Recommended
Recommended
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Theratechnologies

< Previous 1 2 3 Next >
Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future Pak
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports Financial Results for the Second Quarter 2025
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Announce Second Quarter 2025 Financial Results
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports on its Annual Meeting of Shareholders
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Provides Update on Sale Process
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Resumes Distribution of EGRIFTA SV®
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Provides Update on EGRIFTA SV® Supply
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Resumed Production of EGRIFTA SV®
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.